SHEA is one of 20 organizations urging Congress to enact legislation in support of IDSA’s ‘Support Limited Population Antibacterial Drug (LPAD)’ initiative. The goal of LPAD is to create a new regulatory pathway for antibiotics (similar to that available for Orphan Drugs) that target special or limited patient populations—namely those suffering from serious or life-threatening infections with few or no satisfactory treatment options. The new pathway will encourage the development of antibiotics that address the greatest unmet needs (mainly caused by resistance) and get them to patients faster. SHEA signed onto this letter encouraging introduction of LPAD legislation that was sent to Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) in the U.S. Senate and Representatives Philip Gingrey (R-GA) and Gene Green (D-TX) in the U.S. House on July 31, 2013.

View PDF (88 KB)